CDNF Safe in Advanced Parkinson’s, Trial Results Show

CDNF Safe in Advanced Parkinson’s, Trial Results Show
Treatment with cerebral dopamine neurotrophic factor (CDNF), developed by Herantis Pharma, was safe and well-tolerated among patients with advanced-stage Parkinson’s disease, according to topline results from a Phase1/2 clinical trial. The therapy also showed promise in measures of dopaminergic function in some patients. CDNF is based on a protein naturally found in the blood and cerebrospinal fluid (CSF), the liquid ... read more
Source: Parkinson’s News TodayPublished on 2020-02-27By Patricia Inacio, PhD